|
Parrado A, Rubio G, Serrano M, De la Morena-Barrio ME, Ibanez-Mico S, Ruiz-Lafuente N, Schwartz-Albiez R, Esteve-Sole A, Alsina L, Corral J, Hernandez-Caselles T. Dissecting the transcriptional program of phosphomannomutase 2-deficient cells: Lymphoblastoide B cell lines as a valuable model for congenital disorders of glycosylation studies. Glycobiology. 2022 Mar 19;32(2):84-100. doi: 10.1093/glycob/cwab087. PubMed PMID: 34420056.
AÑO: 2022; IF: 4.3
|
34420056
|
Molina ML, Garcia-Bernal D, Salinas MD, Rubio G, Aparicio P, Moraleda JM, Martinez S, Valdor R. Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression. Front Cell Dev Biol. 2022 Mar 18;10:797945. doi: 10.3389/fcell.2022.797945. eCollection 2022. PubMed PMID: 35419364; PubMed Central PMCID: PMC8997287.
AÑO: 2022; IF: 5.5
|
|
Hernandez-Caselles T, Rubio G, Campanero MR, del Pozo MA, Muro M, Sanchez-Madrid F, Aparicio P. ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes. Eur J Immunol. 1993 Nov;23(11):2799-806. doi: 10.1002/eji.1830231112. PubMed PMID: 8223855.
AÑO: 1993; IF: 6.688
|
|
Rubio G, Ferez X, Mora A, Galvez J, Chicano A, Garcia-Penarrubia P. Beta1 integrin triggering affects leukemic cell line sensitivity to natural killer cells. Cancer Immunol Immunother. 2002 May;51(3):130-8. doi: 10.1007/s00262-002-0264-8. Epub 2002 Feb 28. PubMed PMID: 11941451.
AÑO: 2002; IF: 6.63
|
|
Garcia-Penarrubia P, Lorenzo N, Galvez J, Campos A, Ferez X, Rubio G. Study of the physical meaning of the binding parameters involved in effector-target conjugation using monoclonal antibodies against adhesion molecules and cholera toxin. Cell Immunol. 2002 Feb;215(2):141-50. doi: 10.1016/s0008-8749(02)00023-0. PubMed PMID: 12202151.
AÑO: 2002; IF: 4.178
|